Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexmedetomidine after COVID-19 ARDS sedation withdrawal and late neuroinflammation
2020-004802-70Phase 3Active
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of dexmedetomidine in coronavirus disease 2019 (COVID-19), acute respiratory distress syndrome (ARDS) and delirium (2 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Persistent neuroinflammation on PET-MRI at 12 months. Started Mar 2021; status: active.
02
Drugs
dexmedetomidine
03
Conditions
coronavirus disease 2019 (COVID-19)acute respiratory distress syndrome (ARDS)delirium
Beyond the preview
Go deeper on 2020-004802-70.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004802-70.